Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 43

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 43
---
 articles of association and our indemnification agreements
is not complete and is qualified in its entirety by reference to these documents, each of which will be filed as an exhibit to this registration
statement to which this prospectus forms a part.

The limitation of liability and indemnification
provisions in our articles of association may discourage shareholders from bringing a lawsuit against our directors for breach of their
fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action,
if successful, might benefit us and our shareholders. A shareholder’s investment may be harmed to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions.

We maintain a general liability insurance policy
that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their
capacities as directors or officers.

In any placement agent agreement we enter into
in connection with the sale of Common Shares being registered hereby, the placement agent will agree to indemnify, under certain conditions,
us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.

Item 7. Recent Sales of Unregistered Securities.

Set forth below are the
sales of all unregistered securities of ours sold by us within the past three years (i.e., since January 1, 2022, up to the date of this
registration statement) which were not registered under the Securities Act. We believe that each of such issuances was exempt from registration
under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation S under the Securities Act.

<div align='center'>II-1</div>

On February 8, 2022, we entered into a private
placement agreement with Xylo Technologies Ltd., or Xylo, pursuant to which we will raise approximately CAD$1.6 million (approximately
$1.25 million). As consideration for the agreement, we agreed to issue Xylo 2,208 units, or the Xylo Units at a subscription price of
CAD$720.00 (approximately $570.00) per Xylo Unit. Each Xylo Unit is comprised of one Common Share and one warrant to purchase one Common
Share. Each warrant will be exercisable for a period of 18 months into one additional Common Share at a price per share of CAD$1,800.